BB-2516 oral inhibitor of matrix metalloproteinase: Will begin shortly a Phase II U.S. trial in ovarian cancer. A U.K. Phase II trial in ovarian and colorectal

British Biotech plc (BBIOY), Oxford, U.K. Product: BB-2516 oral inhibitor of matrix metalloproteinase Indication: Solid tumors Status: Will begin shortly a Phase II U.S. trial in ovarian cancer. A U.K...